Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic Profiles

Archive ouverte

Fenwarth, Laurène | Podvin, Benjamin | Vasseur, Loïc | Lebon, Delphine | Couillez, Guillaume | Berthon, Céline | Caulier, Alexis | Fournier, Elise | Bories, Claire | Carpentier, Benjamin | Tricot, Sabine | Wattebled, Kevin‐james | Roche-Lestienne, Catherine | Lestringant, Valentin | Hauspie, Carine | Celli-Lebras, Karine | Heiblig, Maël | Dombret, Hervé | Itzykson, Raphael | Marolleau, Jean‐pierre | Garçon, Loïc | Preudhomme, Claude | Duployez, Nicolas | Boyer, Thomas

Edité par CCSD ; Wiley -

International audience. The evolution of acute myeloid leukemia (AML) classifications has progressively shifted the diagnostic focus toward genetic criteria. Nevertheless, morphology remains a key element in clinical practice, often serving as the initial trigger for additional molecular investigations. The diagnosis of acute erythroleukemia (AEML), initially defined by the FAB group, is no longer recognized as a distinct entity in the latest WHO and ICC classifications. Some studies have indicated that AEML shares similarities with myelodysplastic neoplasms, including a high frequency of TP53 mutations and adverse karyotypes. Here, we conducted a retrospective analysis in adults with AEML defined using historical morphologic criteria (≥ 50% erythroid precursors and ≥ 20% blasts among non‐erythroid cells). In contrast to older patients, young adults (18–60 years) exhibit unique genetic profiles including a high prevalence of normal karyotypes (65%), NPM1 (35%) and UBTF (23%) mutations. AEML morphology in NPM1 ‐mutated cases did not impact clinical outcomes but was associated with specific molecular features, including an enrichment of WT1 and cohesin gene mutations. In this age group, our findings support that morphologically defined AEML often corresponds to AML according to current genetic criteria, consistent with recent classification systems that prioritize molecular features over morphology.

Consulter en ligne

Suggestions

Du même auteur

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

Archive ouverte | Dombret, Hervé | CCSD

International audience. Introduction. AML treatment options have been recently enriched. New agents like gemtuzumab ozogamicin (GO), FLT3 or IDH inhibitors, or CPX-351 have been approved for some patient subsets. Le...

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Archive ouverte | Vasseur, Loïc | CCSD

International audience. Abstract Background In the era of personalized medicine, the establishment of preclinical models of cancer that faithfully recapitulate original tumors is essential to potentially guide clini...

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

Archive ouverte | Duployez, Nicolas | CCSD

International audience. Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML,...

Chargement des enrichissements...